← All trials
NCT06263231
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 28, 2024
- Primary completion
- Dec 31, 2027
- Completion date
- Dec 31, 2028
- First posted
- Feb 16, 2024
- Last posted
- Nov 4, 2024
- Enrollment
- 333
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Intensity TherapeuticsLead sponsor
- Premier Research GroupCollaborator
- Johns Hopkins UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.